Komipharm Obtains Export License for ASF Vaccine, PAX-1 Clinical Progress...1Q Separate Net Income Turns Positive

Consolidated revenue KRW 11.9B (-17% YoY), operating profit KRW 0.3B (vs KRW 1.96B YoY)
Separate net income KRW 1.33B (vs KRW 0.53B YoY), turning to black
ASF (African Swine Fever) live attenuated vaccine obtained export product license (April 2026)
PAX-1 glioblastoma phase 2 met primary endpoint; final report in preparation
Treasury shares acquired: 155,619 shares (approx. KRW 1.13B) completed in Feb 2026
PPS (Public Procurement Service) animal drug supply contract increased to KRW 10.08B (from KRW 5.13B)
Consolidated net debt KRW 21.04B (gearing ratio 22.29%), up from KRW 12.26B at prior year-end
R&D expense KRW 1.28B (10.22% of revenue), maintaining high R&D intensity
16th convertible bonds outstanding KRW 12B (conversion price KRW 5,330)